Israel: Experimental drugs can cure 100% of severely ill patients with COVID-19
- Subversive discovery: Can lymph nodes promote the success of cancer immunotherapy?
- Major Discovery: Cancer cell PD-L1 does not inhibit T cell toxicity
- The new coronavirus may kill cancer cells and achieve a permanent cure!
- Why did the Alzheimer’s drug candidate BACE1 inhibitor fail?
- LRTI Death: Research spanning 80 years confirms for the first time
- The decline of the global antibiotic market is threatening the development of new drugs
Israel: Experimental drugs can cure 100% of severely ill patients with COVID-19
- More than 1 million Chinese died after China quit “Zero-COVID policy”?
- Why is Vinyl chloride listed as a Class A “known human carcinogen” ?
- First human trial of HIV gene therapy: A one-time cure will be achieved if successful!
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
Israel: Experimental drugs can cure 100% of severely ill patients with COVID-19. The magic drug is here?
According to a foreign media report on December 22, the Israeli biotechnology company Amorphical announced on the same day that in the phase 2 clinical trial of the company’s COVID-19 pneumonia drug “Amor-18”, 18 patients were treated for moderate and severe COVID-19 pneumonia.
All patients recovered and were discharged from the hospital within a few days. Of the 19 patients who received placebo-controlled treatment, 6 were transferred to the intensive care unit and 2 died.
In clinical trials, 18 patients with moderate and severe COVID-19 pneumonia recovered and were discharged from the hospital within a few days
According to reports, the trial was conducted at the Zief Medical Center in Zefat, Israel, and was led by Dr. Kamal Abu Jabbar and Dr. Nashat Abu Saleh, directors of the COVID-19 virus department of the hospital.
As part of the humanitarian care, two other patients with very serious conditions also took the drug and both recovered and were discharged from the hospital. Dr. Saleh said: “Because the patient who received the medication recovered within a few days and was discharged from the hospital and returned home, it was 100% successful.”
Amor-18, using amorphous calcium carbonate (ACC) as the main ingredient, is taken orally or inhaled through aerosol. According to Amorphical, ACC has the ability to adjust the acid pH around each cell.
These changes affect the ability of the coronavirus to penetrate cells and replicate, so the drug can prevent the spread of the virus, thereby preventing the patient’s condition from getting worse.
Amorphical claims that amorphous calcium carbonate (ACC) has great potential in treating diseases
The company’s CEO Yossi Ben added that Amor-18 has “anti-inflammatory, safe, effective, easy to use and other advantages”, and it can fight against all new coronavirus variants including Delta and Omicron. The entire SARS virus family.
Amorphical said that it has studied ACC in five other clinical trials and has proven its safety in the treatment of various diseases. In the company’s previous research, the adjustment of pH by ACC nanoparticles caused the metabolism of cancer cells to shift to oxidative phosphorylation, reducing the growth rate of tumors, reducing the ability of cancer cells to invade and metastasize, and enhance the immune system’s ability to defeat tumors.
In addition, ACC also has great potential in reversing bone degeneration, accelerating repairs that affect the verification of autoimmune diseases, reducing pain, improving fertility and improving athletic performance.
Screenshots of public information on clinical trials
According to public information, Amorphical initiated a study on the use of ACC to treat COVID-19 pneumonia in February this year, and submitted a formal clinical trial application on May 19. “We are very excited about the results of the clinical trial.
It brings real hope to people infected with the coronavirus in Israel and around the world, especially with the rise of the fifth wave of the epidemic and the rapid spread of the Omicron variant. , This is particularly encouraging.” Yossi Ben said.
According to reports, Israel’s Zief Medical Center, Shamir Medical Center, Kaplan and Tel Aviv Mahani Hayeswa Medical Center are already conducting a larger trial. In the near future, this drug will also be tested in other countries.
At present, seven hospitals in Brazil have announced that they will participate, and other medical centers in Europe and the United States are expected to join soon.
Israel: Experimental drugs can cure 100% of severely ill patients with COVID-19
(source:internet, reference only)
Disclaimer of medicaltrend.org
